No Additional Benefits in Vaginal Estradiol Tablets, Moisturizers for Postmenopausal Vulvovaginal SymptomsJune 14, 2018
Prescribed vaginal estradiol tablets and over-the-counter vaginal moisturizers may not be more effective than placebos for postmenopausal vulvovaginal symptoms.
Equol-containing nutraceuticals may be beneficial for postmenopausal women with vaginal symptoms.
The FDA approval was supported by findings from a Phase 3, randomized, double-blind, placebo-controlled study that evaluated Imvexxy (4mcg and 10mcg) vs placebo from baseline to week 12.
The two most prevalent HIV symptoms, fatigue and muscle aches, are more common in women than men and can worsen with menopause.
UTIs present clinically as dysuria, with symptoms of frequent and urgent urination secondary to irritation of the urethral and bladder mucosa.
Body mass index BMI at a cut-point of 30 kg/m2 may not be an appropriate indicator of obesity in postmenopausal women.
The USPSTF has updated its recommendations on the use of menopausal hormone therapy for the primary prevention of chronic conditions.
Early menopause risk is highest in weight-cycling and severely underweight women.
The researchers found no long-term increase in either all-cause or cause-specific mortality among women who received hormone therapy for up to 5.6 years or 7.2 years, depending on the type of therapy.
Women who experienced early menopause were 2.4 times more likely to develop diabetes.
Intrarosa provides an additional treatment option for women with dyspareunia caused by vulvar and vaginal atrophy.
Women may have a higher risk of type 2 diabetes with low levels of sex hormone-binding globulin and high levels of total estradiol.
Women who experience more nighttime hot flashes are more likely to experience worsening mood during menopause.
The American Heart Association found that during menopausal transition, women have a rapid increase in metabolic syndrome severity.
Vitamin D deficiency is especially prevalent in postmenopausal women, and recommendations from current guidelines are inconsistent regarding vitamin D use.
Researchers confirmed increased risks for infertility and natural menopause before age 50 in women who are either active smokers or regularly exposed to secondhand smoke.
New guidelines issued by the Endocrine Society and published in the Journal of Clinical Endocrinology and Metabolism suggest that clinicians should provide patients with individualized menopause treatments.
Vitamin D did not improve bone and muscle outcomes in postmenopausal women.
Women prescribed SSRIs for menopausal symptoms had a sustained increased risk for fracture.
Should oral progesterone be prescribed in combination with vaginal estrogen?
Daily calcium and vitamin D supplements did not relieve the frequency or severity of joint symptoms in postmenopausal women.
The FDA has approved paroxetine, a selective seratonin reuptake inhibitor, to treat moderate to severe hot flashes in women with menopause.
Omega-3 supplements can help constipation in postmenopausal women taking calcium and vitamin D supplements.
Consuming soy products and fiber did not prevent the onset of hot flashes and night sweats associated with menopause.
Can thyroid hormone replacement therapy affect bone density?
Could a vegetarian diet be contributing to an older woman's alopecia?
U.S. Preventive Services Task Force performed a review of nine clinical trials to assess the effectiveness of menopausal hormone therapy in preventing chronic conditions.
If follicle-stimulating hormone is >20 mIU/mL, most clinicians counsel patients against contraception, as the risk of pregnancy is virtually nil.
Women who experience early menopause are at increased risk for osteoporosis later in life compared with women who reach menopause after the age of 47.
Ongoing use of combined hormone therapy for 10 years or longer doubled the risk for breast cancer.